InspireMD outlines Q3 2025 FDA approval target for CGuard Prime

Stock Information for InspireMD Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InspireMD Inc.

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
InspireMD Reports First Quarter 2025 Financial Results
InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference
InspireMD to Announce First Quarter 2025 Financial Results
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.